Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
- Monday, November 21, 2022, 7:01
- Finance
- Add a comment
MORRISVILLE, N.C., Nov. 21, 2022 /PRNewswire/ — Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug…
About the Author
adminasapcorp has written 41562 stories on this site.